Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 390

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 390
---
 of the Kineta-Yumanity Merger in December 2022, the number of authorized shares of common stock of the Company was adjusted to 125,000,000 with a par value of $0.001 and all non-votingshares became voting shares. As of December 31, 2024, there were 12,265,496 shares issued and outstanding. F-137

KINETA, INC. Notes to Consolidated Financial Statements Common stock reserved for future issuance consisted of the following as the period presented:

|                                                                                         |     | December 31, 2024 |       |
|:----------------------------------------------------------------------------------------|:----|:------------------|------:|
|                                                                                         |     | -in thousands     |       |
| Shares reserved for stock options to purchase common stock under equity incentive plans |     |                   | 2,331 |
| Shares reserved for future issuance of equity awards                                    |     |                   |   766 |
| Shares reserved for exercise of warrants                                                |     |                   | 2,718 |
| Total                                                                                   |     |                   | 5,815 |

On April 22, 2024, the Company entered into the Settlement Agreement with RLB to continue RLB’s investment in the Company and to resolve any and all potential claims or causes of action in connection with RLB’s failure to purchase $2.5 million of shares of the Company’s common stock pursuant to a financing agreement, dated as of June 5, 2022, as amended on October 24, 2022, December 5, 2022, March 29, 2023, May 1, 2023, July 21, 2023 and October 13, 2023. Pursuant to the Settlement Agreement, on April 23, 2024, the Company received cash proceeds of $500,000 from RLB and on May 1, 2024, the Company issued 903,995 shares of its common stock to RLB. During the year ended December 31, 2024, the Company issued 786,000 shares of its common stock upon exercise of warrants and received proceeds of $2,000. The exercise price of all shares exercised was $0.001. During the year ended December 31, 2024, the Company issued 91,000 shares of its common stock for license expenses and recorded $250,000 as license expense within research and development expense. During the year ended December